youtube_live
Q3 2026 earnings • in 4 days
See detailschevron_right
COGT:NASDAQ
Cogent Biosciences Inc
$29.69
arrow_downward
-5.72%(-1.80) 1D
Nov 5, 12:34:06 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for COGT...
Open
$31.34
High
$31.41
Low
$29.16
Mkt. cap
5.15B
Avg. vol.
2.16M
Volume
1.28M
52-wk high
$43.73
52-wk low
$13.93
EPS
-$2.14
Beta
0.36
Shares outstanding
173.52M
No. of employees
258
Open
$31.34
High
$31.41
Low
$29.16
Mkt. cap
5.15B
Avg. vol.
2.16M
Volume
1.28M
52-wk high
$43.73
52-wk low
$13.93
EPS
-$2.14
Beta
0.36
Shares outstanding
173.52M
No. of employees
258
News stories
From web sources and news partners
marketscreener.com
·
8 minutes ago
Nasdaq futures slip on chip weakness; S&P 500 holds gains
MS NOW
·
40 minutes ago
Nasdaq plummets, Dow slides more than 1,000 points
Quartz
·
33 minutes ago
Nasdaq plunges 4% on pace for correction territory as election results spook AI and chip stocks
TradingView
·
32 minutes ago
Midday Pulse: S&P 500 top intraday gainers
About Cogent Biosciences Inc
CEO-
Employees258
Founded2014
HeadquartersWaltham, Massachusetts, United States
SectorBiotechnology
Industry-
Websitecogentbio.com
Analyst ratings
Based on 9 analysts giving stock ratings to COGT in the past 3 months
Strong buy
Buy
8
Hold
1
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for COGT in the last 3 months.
Highest
Current $29.69
$62.00 (+108.82%)
Average
$54.88 (+84.84%)
Lowest
$45.00 (+51.57%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Laura Prendergast Stifel Nicolaus | Buy | Maintained | $45.00 | +51.6% | 10/27/2026 |
Michael Yee UBS | Buy | Maintained | $60.00 | +102.1% | 10/13/2026 |
Michael Schmidt Guggenheim | Buy | Maintained | $52.00 | +75.1% | 10/06/2026 |
Unknown Analyst Guggenheim | Buy | Maintained | $52.00 | +75.1% | 10/06/2026 |
David Nierengarten Wedbush | Buy | Maintained | $55.00 | +85.2% | 09/16/2026 |
Sam Slutsky LifeSci Capital | Buy | Maintained | $55.00 | +85.2% | 09/15/2026 |
Robert Burns H.C. Wainwright | Buy | Reiterated | $55.00 | +85.2% | 09/16/2026 |
Anupam Rama J.P. Morgan | Buy | Maintained | $62.00 | +108.8% | 09/09/2026 |
Allison Bratzel Piper Sandler | Buy | Maintained | $55.00 | +85.2% | 08/17/2026 |
Ami Fadia Needham | Hold | Reiterated | - | - | 08/11/2026 |
Faisal Khurshid Jefferies | Buy | Initiated | $55.00 | +85.2% | 03/16/2026 |
Colleen M. Kusy Robert W. Baird | Hold | Maintained | $35.00 | +17.9% | 02/19/2026 |
Next call in 4 days
Mon, Nov 9, 7:30 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / -$0.55
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | - | - | - | - |
Cost of goods sold | - | - | - | - |
Cost of revenue | - | - | - | - |
Research and development expenses | 68.99M | 75.56M | 75.36M | 70.81M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 14.37M | 23.93M | 28.24M | 31.83M |
Operating expense | 83.36M | 99.49M | 103.61M | 102.64M |
Total operating expenses | 83.36M | 99.49M | 103.61M | 102.64M |
Operating income | -83.36M | -99.49M | -103.61M | -102.64M |
Other non operating income | -3.00K | 900.00K | -140.00K | -11.00K |
EBT including unusual items | -80.93M | -102.49M | -97.35M | -96.40M |
EBT excluding unusual items | -80.93M | -94.40M | -97.35M | -96.40M |
Income tax expense | - | - | - | - |
Effective tax rate | - | - | - | - |
Other operating expenses | - | - | - | - |
Net income | -80.93M | -102.49M | -97.35M | -96.40M |
Net profit margin | - | - | - | - |
Earnings per share | -0.50 | -0.56 | -0.53 | -0.52 |
Interest and investment income | 3.89M | 5.48M | 7.61M | 7.46M |
Interest expense | -1.46M | -1.29M | -1.21M | -1.22M |
Net interest expenses | 2.43M | 4.19M | 6.40M | 6.24M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -82.71M | -98.86M | -102.98M | -101.90M |
Gain or loss from assets sale | - | - | 135.00K | -1.00K |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events